Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs

Area of Science:

• Endocrinology
• Oncology
• Biochemistry

Background:

• Dehydroepiandrosterone (DHEA) is an adrenocortical steroid hormone with demonstrated tumor-inhibitory effects in various experimental models.
• DHEA's anti-cancer properties are linked to the inhibition of glucose-6-phosphate dehydrogenase and the pentose phosphate pathway, crucial for NADPH production and cellular proliferation.
• The therapeutic application of DHEA is limited by its metabolism into sex hormones, leading to androgenic and estrogenic side effects.

Purpose of the Study:

• To investigate the anti-proliferative and cancer-preventive potential of a novel synthetic steroid.
• To develop a DHEA analog that retains anti-cancer activity without exhibiting sex hormonal side effects.

Main Methods:

• Administration of DHEA to laboratory mice and rats to assess tumor development inhibition.
• Evaluation of DHEA's effects on two-stage skin tumorigenesis, including tumor initiation and promotion.
• Development and testing of a synthetic steroid, 16 alpha-fluoro-5-androsten-17-one, for anti-proliferative and hormonal activities.

Main Results:

• DHEA administration inhibited the development of experimental tumors in breast, lung, colon, liver, skin, and lymphatic tissues.
• DHEA treatment suppressed tumor initiation and reduced hyperplasia and papilloma promotion in a mouse skin cancer model.
• The synthetic steroid 16 alpha-fluoro-5-androsten-17-one demonstrated anti-proliferative and cancer-preventive activity comparable to DHEA, but without androgenic or estrogenic effects.

Conclusions:

• DHEA exhibits significant anti-cancer properties by modulating the pentose phosphate pathway.
• The synthetic steroid 16 alpha-fluoro-5-androsten-17-one represents a promising therapeutic agent with potential cancer-preventive benefits and a reduced side effect profile compared to DHEA.